Kyverna Therapeutics Inc（KYTX）财务数据KYTXKyverna Therapeutics Inc

Evaluating the bottom line, Kyverna Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -87.24%, provide a clear picture of how effectively KYTX converts its operational activities into shareholder value.

In the context of the broader market, KYTX competes directly with industry leaders such as FENC and EDIT. With a market capitalization of $395.18M, it holds a significant position in the sector. When comparing efficiency, KYTX's gross margin of N/A stands against FENC's 95.97% and EDIT's 100.00%. Such benchmarking helps identify whether Kyverna Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Kyverna has reported consistent net losses, with a net income of -39,728,000 USD in Q1 2026 and a negative EPS of -0.63. The company has a current ratio of 9.06, indicating strong liquidity, but the overall financial performance is concerning due to ongoing losses.